CN107635558A - 布罗莫结构域抑制剂 - Google Patents
布罗莫结构域抑制剂 Download PDFInfo
- Publication number
- CN107635558A CN107635558A CN201680034663.2A CN201680034663A CN107635558A CN 107635558 A CN107635558 A CN 107635558A CN 201680034663 A CN201680034663 A CN 201680034663A CN 107635558 A CN107635558 A CN 107635558A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- hydrogen
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *[C@@]1(C2)CCCC2*1 Chemical compound *[C@@]1(C2)CCCC2*1 0.000 description 18
- TZIMMOSIODNDHN-UHFFFAOYSA-N CC(c(cc1)c2cc1F)=CN(C)C2=O Chemical compound CC(c(cc1)c2cc1F)=CN(C)C2=O TZIMMOSIODNDHN-UHFFFAOYSA-N 0.000 description 2
- QJXJBMFDTPYJQY-UHFFFAOYSA-N CC(c1ccccc11)=CN(C)C1=O Chemical compound CC(c1ccccc11)=CN(C)C1=O QJXJBMFDTPYJQY-UHFFFAOYSA-N 0.000 description 2
- AIOQEYAWCRMDTR-UHFFFAOYSA-N BCc(cc1Br)cc2c1[o]c(C1CC1)n2 Chemical compound BCc(cc1Br)cc2c1[o]c(C1CC1)n2 AIOQEYAWCRMDTR-UHFFFAOYSA-N 0.000 description 1
- SMCISNFNJDPMEW-UHFFFAOYSA-N C=[Br]c1cc([N+]([O-])=O)c2N=NC(CCc3ccccc3)c2c1 Chemical compound C=[Br]c1cc([N+]([O-])=O)c2N=NC(CCc3ccccc3)c2c1 SMCISNFNJDPMEW-UHFFFAOYSA-N 0.000 description 1
- ZJVMYIQHTGFZQB-UHFFFAOYSA-N CC(C=C1C)=CN(C)C1=O Chemical compound CC(C=C1C)=CN(C)C1=O ZJVMYIQHTGFZQB-UHFFFAOYSA-N 0.000 description 1
- UMDRZTFXBHRFDF-UHFFFAOYSA-N CC(C=C1OC)=CN(C)C1=O Chemical compound CC(C=C1OC)=CN(C)C1=O UMDRZTFXBHRFDF-UHFFFAOYSA-N 0.000 description 1
- KXKOZJDPSAVMQN-UHFFFAOYSA-N CC/S(/Nc1cc(C(C=C2C)=CN(C)C2=O)cc2c1nn[n]2Cc(cc1)ccc1F)=C\C Chemical compound CC/S(/Nc1cc(C(C=C2C)=CN(C)C2=O)cc2c1nn[n]2Cc(cc1)ccc1F)=C\C KXKOZJDPSAVMQN-UHFFFAOYSA-N 0.000 description 1
- CODOYVUZDHZYRZ-UHFFFAOYSA-N CC/S(/Nc1cc(C(C=C2C)=CN(C)C2=O)cc2c1nn[n]2Cc1ccccc1)=C/C Chemical compound CC/S(/Nc1cc(C(C=C2C)=CN(C)C2=O)cc2c1nn[n]2Cc1ccccc1)=C/C CODOYVUZDHZYRZ-UHFFFAOYSA-N 0.000 description 1
- FBOUGHDVQYCHDW-UHFFFAOYSA-N CC1=CC(C(C=C(C(CC2)C3)N2S(C)(=O)=O)=C3OCC2CC2)=CN(C)C1=O Chemical compound CC1=CC(C(C=C(C(CC2)C3)N2S(C)(=O)=O)=C3OCC2CC2)=CN(C)C1=O FBOUGHDVQYCHDW-UHFFFAOYSA-N 0.000 description 1
- SAQSMGJDYKSIEG-UHFFFAOYSA-N CC1=CNC(C(CC2)(F)F)N2C1=O Chemical compound CC1=CNC(C(CC2)(F)F)N2C1=O SAQSMGJDYKSIEG-UHFFFAOYSA-N 0.000 description 1
- CHZMWQYAJSMPJO-UHFFFAOYSA-N CCOc(cc(CN(C)S1(=O)=O)c1c1)c1C(C=C1C)=CN(C)C1=O Chemical compound CCOc(cc(CN(C)S1(=O)=O)c1c1)c1C(C=C1C)=CN(C)C1=O CHZMWQYAJSMPJO-UHFFFAOYSA-N 0.000 description 1
- ADKKKJSPASMXOK-UHFFFAOYSA-N CN(C=C(c1c2[o]c(-c3ccccc3)cc2cc(S(C)(=O)=O)c1)c1c2cccc1)C2=O Chemical compound CN(C=C(c1c2[o]c(-c3ccccc3)cc2cc(S(C)(=O)=O)c1)c1c2cccc1)C2=O ADKKKJSPASMXOK-UHFFFAOYSA-N 0.000 description 1
- VGEBGGQMCVKLEW-UHFFFAOYSA-N CN(C=C(c1c2cccc1)c(cc(c(CC1)c3)N1S(C)(=C)=O)c3OCC1CC1)C2=O Chemical compound CN(C=C(c1c2cccc1)c(cc(c(CC1)c3)N1S(C)(=C)=O)c3OCC1CC1)C2=O VGEBGGQMCVKLEW-UHFFFAOYSA-N 0.000 description 1
- HCGHJQUBUGIUBL-UHFFFAOYSA-N CN(Cc(c1c2)cc(OCC3CC3)c2C(c2ccccc22)=CN(C)C2=O)S1(=O)=O Chemical compound CN(Cc(c1c2)cc(OCC3CC3)c2C(c2ccccc22)=CN(C)C2=O)S1(=O)=O HCGHJQUBUGIUBL-UHFFFAOYSA-N 0.000 description 1
- LGHSRAMGJFIEDF-UHFFFAOYSA-N CS(Cc(cc1Br)cc2c1[o]c(C1CC1)n2)(=O)=O Chemical compound CS(Cc(cc1Br)cc2c1[o]c(C1CC1)n2)(=O)=O LGHSRAMGJFIEDF-UHFFFAOYSA-N 0.000 description 1
- OWIJBXQCAIHIAB-UHFFFAOYSA-N OCc(cc1Br)cc2c1[o]c(C1CC1)n2 Chemical compound OCc(cc1Br)cc2c1[o]c(C1CC1)n2 OWIJBXQCAIHIAB-UHFFFAOYSA-N 0.000 description 1
- SPVXPDGFRIXIRA-UHFFFAOYSA-N [O-][N+](c1c2c(F)n[n](CC(C=C3)=CCC3F)c2cc(Br)c1)=O Chemical compound [O-][N+](c1c2c(F)n[n](CC(C=C3)=CCC3F)c2cc(Br)c1)=O SPVXPDGFRIXIRA-UHFFFAOYSA-N 0.000 description 1
- OEZQLYAQVANSGW-UHFFFAOYSA-N [O-][N+](c1cc(Br)cc2c1cn[n]2Cc1ccccc1)=O Chemical compound [O-][N+](c1cc(Br)cc2c1cn[n]2Cc1ccccc1)=O OEZQLYAQVANSGW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148098P | 2015-04-15 | 2015-04-15 | |
| US62/148,098 | 2015-04-15 | ||
| PCT/US2016/027874 WO2016168682A2 (en) | 2015-04-15 | 2016-04-15 | Bromodomain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107635558A true CN107635558A (zh) | 2018-01-26 |
Family
ID=57126317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680034663.2A Pending CN107635558A (zh) | 2015-04-15 | 2016-04-15 | 布罗莫结构域抑制剂 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9908885B2 (OSRAM) |
| EP (2) | EP3283077B1 (OSRAM) |
| JP (1) | JP6856543B2 (OSRAM) |
| KR (1) | KR20170135938A (OSRAM) |
| CN (1) | CN107635558A (OSRAM) |
| AR (1) | AR104259A1 (OSRAM) |
| AU (1) | AU2016249273B2 (OSRAM) |
| CA (1) | CA2982588A1 (OSRAM) |
| CL (1) | CL2017002606A1 (OSRAM) |
| CO (1) | CO2017011484A2 (OSRAM) |
| EA (1) | EA201792229A1 (OSRAM) |
| EC (1) | ECSP17070706A (OSRAM) |
| ES (1) | ES2868355T3 (OSRAM) |
| HK (1) | HK1243326A1 (OSRAM) |
| IL (1) | IL255006A0 (OSRAM) |
| MX (1) | MX2017013207A (OSRAM) |
| PE (1) | PE20180258A1 (OSRAM) |
| PH (1) | PH12017501888A1 (OSRAM) |
| SG (1) | SG11201708470SA (OSRAM) |
| TW (1) | TW201643153A (OSRAM) |
| WO (1) | WO2016168682A2 (OSRAM) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108137539A (zh) * | 2015-08-12 | 2018-06-08 | 尼奥迈德研究所 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| CN108516973A (zh) * | 2018-03-30 | 2018-09-11 | 广西师范大学 | 3-苯并噻唑-1-(3-二甲氨基)丙基喹啉-4-酮衍生物及其制备方法和应用 |
| CN112174945A (zh) * | 2019-07-02 | 2021-01-05 | 四川大学 | 具有抗癌作用的吲唑类化合物及其制备方法和用途 |
| CN112823152A (zh) * | 2018-07-23 | 2021-05-18 | 赛尔基因昆蒂赛尔研究公司 | 用于制备布罗莫结构域抑制剂的方法 |
| CN114014842A (zh) * | 2021-11-04 | 2022-02-08 | 中国药科大学 | 一种杂环酮类化合物与其组合物及其制备方法和应用 |
| CN114286818A (zh) * | 2019-07-02 | 2022-04-05 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| AU2016305513A1 (en) | 2015-08-11 | 2018-03-08 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN108314680A (zh) * | 2017-01-16 | 2018-07-24 | 凯惠科技发展(上海)有限公司 | 一种含芳环化合物、其制备方法、药物组合物及应用 |
| EP3612522A4 (en) | 2017-04-18 | 2021-07-07 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| CN107098844B (zh) * | 2017-05-17 | 2019-07-30 | 许昌学院 | 一种c-5位硝基取代的酰基吲哚啉类化合物的合成方法 |
| BR112020012527A2 (pt) * | 2017-12-20 | 2020-11-24 | Betta Pharmaceuticals Co., Ltd | composto que funciona como inibidor de proteína com bromodomínio, e composição |
| CN112236172A (zh) | 2018-01-30 | 2021-01-15 | 福宏治疗公司 | 用于治疗病症的方法和化合物 |
| KR20210125471A (ko) | 2018-10-05 | 2021-10-18 | 안나푸르나 바이오, 인코포레이티드 | Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물 |
| WO2020092638A1 (en) | 2018-10-30 | 2020-05-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| WO2020160193A2 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| WO2020160192A1 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3917529A4 (en) | 2019-01-29 | 2022-11-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| US12497395B2 (en) * | 2019-04-24 | 2025-12-16 | Convergene, Llc | Small molecule bromodomain inhibitors and uses therof |
| WO2021022163A2 (en) * | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| TWI877297B (zh) | 2020-01-29 | 2025-03-21 | 美商福宏治療公司 | 化合物及其用途 |
| JP2023536139A (ja) * | 2020-07-29 | 2023-08-23 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| WO2023283263A1 (en) | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| WO2023090859A1 (ko) * | 2021-11-17 | 2023-05-25 | 일동제약(주) | 아이속사졸 유도체의 제조 방법 및 그의 신규한 중간체 |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3590036A (en) * | 1968-11-18 | 1971-06-29 | George Y Lesher | Naphthyridine-3-carboxylic acids,their derivatives and preparation thereof |
| WO2014145051A1 (en) * | 2013-03-15 | 2014-09-18 | Jiazhong Zhang | Heterocyclic compounds and uses thereof |
| CN105828820A (zh) * | 2013-10-18 | 2016-08-03 | 赛尔基因昆蒂赛尔研究公司 | 布罗莫结构域抑制剂 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1349418A (en) * | 1919-08-05 | 1920-08-10 | George F Flynn | Motor-support |
| DE2011970A1 (en) | 1970-03-13 | 1971-11-18 | CH. Boehringer Sohn, 6507 Ingelheim | Imidazo-(1, 2-a)- pyrimidines prepn |
| US3635667A (en) | 1970-07-23 | 1972-01-18 | Fmc Corp | Drycleaning with hydrogen peroxide |
| GB1322318A (en) * | 1971-05-19 | 1973-07-04 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and esters |
| BE786028A (fr) | 1971-07-08 | 1973-01-08 | Boehringer Sohn Ingelheim | 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer |
| DE2356005A1 (de) | 1973-11-09 | 1975-05-22 | Boehringer Sohn Ingelheim | Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung |
| AU577105B2 (en) | 1985-04-02 | 1988-09-15 | T.P.O. :Pharmachim: | Acylaminic penicillin derivatives |
| US6117940A (en) | 1997-10-17 | 2000-09-12 | Mjalli; Adnan M. M. | Amino-ketone solid support templates |
| KR100850728B1 (ko) * | 2000-06-12 | 2008-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도 |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| ATE386741T1 (de) | 2002-09-26 | 2008-03-15 | Pfizer | Pyrazolamide zur behandlung von hiv-infektionen |
| JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| EP1667981A4 (en) * | 2003-09-23 | 2008-08-13 | Merck & Co Inc | ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS |
| CN1856476A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉酮钾通道抑制剂 |
| KR100703068B1 (ko) | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| TW200536830A (en) * | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| CN1938296A (zh) | 2004-04-01 | 2007-03-28 | 安斯泰来制药有限公司 | 作为腺苷拮抗剂的吡嗪衍生物及其制药用途 |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| KR100781704B1 (ko) | 2005-04-20 | 2007-12-03 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| NI200800025A (es) | 2005-07-26 | 2009-03-03 | Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa | |
| JP5049970B2 (ja) | 2005-07-26 | 2012-10-17 | サノフイ | Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体 |
| US20070099911A1 (en) | 2005-10-28 | 2007-05-03 | Wyeth | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
| CN101426373A (zh) * | 2006-03-10 | 2009-05-06 | 神经原公司 | 哌嗪基氧代烷基四氢异喹啉及相关类似物 |
| GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
| ATE490243T1 (de) | 2006-12-27 | 2010-12-15 | Sanofi Aventis | Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate |
| WO2008077550A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| ES2625266T3 (es) | 2006-12-27 | 2017-07-19 | Sanofi | Derivados de isoquinolona sustituidos con cicloalquilamina |
| US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| MX2010008375A (es) | 2008-01-30 | 2011-03-04 | Cephalon Inc Star | Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3). |
| EP2313408B1 (en) | 2008-06-25 | 2012-07-11 | Bristol-Myers Squibb Company | Diketopiperidine derivatives as hiv attachment inhibitors |
| WO2010039186A2 (en) * | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| US8283360B2 (en) * | 2008-12-19 | 2012-10-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic derivatives and methods of use thereof |
| IN2012DN03883A (OSRAM) | 2009-10-06 | 2015-09-25 | Millennium Pharm Inc | |
| CN102753545A (zh) | 2009-12-15 | 2012-10-24 | 盐野义制药株式会社 | 具有血管内皮脂酶抑制活性的噁二唑衍生物 |
| US8791113B2 (en) | 2010-06-28 | 2014-07-29 | Merck Patent Gmbh | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| WO2012086735A1 (ja) * | 2010-12-22 | 2012-06-28 | 大正製薬株式会社 | 縮合複素環化合物 |
| RU2017140639A (ru) | 2011-05-23 | 2019-02-12 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
| RU2477723C2 (ru) * | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CA2855019A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| CN103183675A (zh) | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-4抑制剂 |
| WO2013130855A1 (en) * | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| WO2013186229A1 (en) * | 2012-06-11 | 2013-12-19 | Ucb Pharma S.A. | Tnf -alpha modulating benzimidazoles |
| JP2014024838A (ja) * | 2012-06-21 | 2014-02-06 | Taisho Pharmaceutical Co Ltd | 縮合複素環化合物を有効成分として含有する血糖低下作用薬 |
| WO2014015088A1 (en) * | 2012-07-19 | 2014-01-23 | Bristol-Myers Squibb Company | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| WO2014109414A1 (ja) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
| WO2014164596A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| CN105209467B (zh) * | 2013-05-27 | 2018-06-08 | 诺华股份有限公司 | 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途 |
| CN105492439B (zh) | 2013-06-21 | 2019-11-22 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的取代的双环化合物 |
| WO2014205594A1 (en) * | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
| MX355943B (es) * | 2013-06-26 | 2018-05-07 | Abbvie Inc | Carboxamidas primarias como inhibidores de btk. |
| WO2015081189A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| JP6469692B2 (ja) * | 2013-12-09 | 2019-02-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| US10173991B2 (en) * | 2014-01-07 | 2019-01-08 | Bristol-Myers Squibb Company | Sulfone amide linked benzothiazole inhibitors of endothelial lipase |
| US9499551B2 (en) | 2014-01-24 | 2016-11-22 | Confluence Life Sciences, Inc. | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases |
| UA119870C2 (uk) * | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
| MA40943A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40940A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016086200A1 (en) * | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| EP3265453B1 (en) * | 2015-03-05 | 2022-06-29 | Boehringer Ingelheim International GmbH | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
-
2016
- 2016-04-14 AR ARP160101014A patent/AR104259A1/es unknown
- 2016-04-15 CN CN201680034663.2A patent/CN107635558A/zh active Pending
- 2016-04-15 EP EP16780891.4A patent/EP3283077B1/en active Active
- 2016-04-15 SG SG11201708470SA patent/SG11201708470SA/en unknown
- 2016-04-15 EP EP20215944.8A patent/EP3831383A1/en not_active Withdrawn
- 2016-04-15 AU AU2016249273A patent/AU2016249273B2/en not_active Ceased
- 2016-04-15 MX MX2017013207A patent/MX2017013207A/es unknown
- 2016-04-15 ES ES16780891T patent/ES2868355T3/es active Active
- 2016-04-15 WO PCT/US2016/027874 patent/WO2016168682A2/en not_active Ceased
- 2016-04-15 TW TW105111879A patent/TW201643153A/zh unknown
- 2016-04-15 US US15/130,503 patent/US9908885B2/en active Active
- 2016-04-15 KR KR1020177032364A patent/KR20170135938A/ko not_active Withdrawn
- 2016-04-15 PE PE2017002197A patent/PE20180258A1/es not_active Application Discontinuation
- 2016-04-15 HK HK18102785.5A patent/HK1243326A1/zh unknown
- 2016-04-15 CA CA2982588A patent/CA2982588A1/en active Pending
- 2016-04-15 JP JP2017553414A patent/JP6856543B2/ja not_active Expired - Fee Related
- 2016-04-15 EA EA201792229A patent/EA201792229A1/ru unknown
-
2017
- 2017-10-13 CL CL2017002606A patent/CL2017002606A1/es unknown
- 2017-10-15 IL IL255006A patent/IL255006A0/en unknown
- 2017-10-18 PH PH12017501888A patent/PH12017501888A1/en unknown
- 2017-10-24 EC ECIEPI201770706A patent/ECSP17070706A/es unknown
- 2017-11-08 CO CONC2017/0011484A patent/CO2017011484A2/es unknown
-
2018
- 2018-01-12 US US15/870,557 patent/US10494371B2/en active Active
-
2019
- 2019-11-04 US US16/673,839 patent/US10807982B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3590036A (en) * | 1968-11-18 | 1971-06-29 | George Y Lesher | Naphthyridine-3-carboxylic acids,their derivatives and preparation thereof |
| WO2014145051A1 (en) * | 2013-03-15 | 2014-09-18 | Jiazhong Zhang | Heterocyclic compounds and uses thereof |
| CN105828820A (zh) * | 2013-10-18 | 2016-08-03 | 赛尔基因昆蒂赛尔研究公司 | 布罗莫结构域抑制剂 |
Non-Patent Citations (2)
| Title |
|---|
| PUBCHEM: "4-Methyl-6-(2-methyl-1-oxoisoquinolin-4-yl)-1,4-benzoxazin-3-one", 《PUBCHEM》 * |
| STN-REGISTRY: "1349418-35-4", 《STN-REGISTRY》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108137539A (zh) * | 2015-08-12 | 2018-06-08 | 尼奥迈德研究所 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| CN108137539B (zh) * | 2015-08-12 | 2022-01-11 | 尼奥迈德研究所 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| CN114605387A (zh) * | 2015-08-12 | 2022-06-10 | 埃皮吉纳提克斯股份有限公司 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| CN108516973A (zh) * | 2018-03-30 | 2018-09-11 | 广西师范大学 | 3-苯并噻唑-1-(3-二甲氨基)丙基喹啉-4-酮衍生物及其制备方法和应用 |
| CN112823152A (zh) * | 2018-07-23 | 2021-05-18 | 赛尔基因昆蒂赛尔研究公司 | 用于制备布罗莫结构域抑制剂的方法 |
| CN112174945A (zh) * | 2019-07-02 | 2021-01-05 | 四川大学 | 具有抗癌作用的吲唑类化合物及其制备方法和用途 |
| CN114286818A (zh) * | 2019-07-02 | 2022-04-05 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
| CN112174945B (zh) * | 2019-07-02 | 2022-06-07 | 四川大学 | 具有抗癌作用的吲唑类化合物及其制备方法和用途 |
| CN114286818B (zh) * | 2019-07-02 | 2024-09-20 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
| CN114014842A (zh) * | 2021-11-04 | 2022-02-08 | 中国药科大学 | 一种杂环酮类化合物与其组合物及其制备方法和应用 |
| CN114014842B (zh) * | 2021-11-04 | 2024-03-01 | 中国药科大学 | 一种杂环酮类化合物与其组合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201643153A (zh) | 2016-12-16 |
| US20180134710A1 (en) | 2018-05-17 |
| KR20170135938A (ko) | 2017-12-08 |
| WO2016168682A2 (en) | 2016-10-20 |
| AU2016249273A1 (en) | 2017-11-09 |
| US9908885B2 (en) | 2018-03-06 |
| CA2982588A1 (en) | 2016-10-20 |
| US20170050968A1 (en) | 2017-02-23 |
| IL255006A0 (en) | 2017-12-31 |
| ECSP17070706A (es) | 2017-12-01 |
| CL2017002606A1 (es) | 2018-05-18 |
| US10807982B2 (en) | 2020-10-20 |
| MX2017013207A (es) | 2018-02-19 |
| EP3831383A1 (en) | 2021-06-09 |
| EP3283077A2 (en) | 2018-02-21 |
| JP2018511626A (ja) | 2018-04-26 |
| US20200071332A1 (en) | 2020-03-05 |
| AR104259A1 (es) | 2017-07-05 |
| US10494371B2 (en) | 2019-12-03 |
| EP3283077B1 (en) | 2021-03-10 |
| EA201792229A1 (ru) | 2018-05-31 |
| PE20180258A1 (es) | 2018-02-05 |
| HK1243326A1 (zh) | 2018-07-13 |
| ES2868355T3 (es) | 2021-10-21 |
| EP3283077A4 (en) | 2019-01-23 |
| AU2016249273B2 (en) | 2020-07-09 |
| WO2016168682A3 (en) | 2016-12-08 |
| JP6856543B2 (ja) | 2021-04-07 |
| CO2017011484A2 (es) | 2018-01-31 |
| PH12017501888A1 (en) | 2018-03-05 |
| SG11201708470SA (en) | 2017-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10807982B2 (en) | Bromodomain inhibitors | |
| CN108558889B (zh) | 布罗莫结构域抑制剂 | |
| TWI719437B (zh) | Mat2a之雜雙環抑制劑及治療癌症之使用方法 | |
| CN113454085B (zh) | Mat2a的aza杂双环抑制剂和用于治疗癌症的方法 | |
| CN111440189B (zh) | 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用 | |
| CN114728912A (zh) | Mta-协同prmt5抑制剂 | |
| CN108884061B (zh) | 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 | |
| CN113544128A (zh) | Kras-g12c抑制剂 | |
| CN113474347A (zh) | Mat2a的aza杂双环抑制剂和用于治疗癌症的方法 | |
| TW201835083A (zh) | 雜芳基并［４，３－ｃ］嘧啶－５－胺類衍生物、其製備方法及其在醫藥上的使用 | |
| CN101778849A (zh) | 可用作gaba调节剂的稠合喹啉衍生物 | |
| WO2020215998A1 (zh) | 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途 | |
| CN108463462B (zh) | 苯二氮䓬类作为溴结构域抑制剂 | |
| CN115109061B (zh) | 三环化合物 | |
| CN108314680A (zh) | 一种含芳环化合物、其制备方法、药物组合物及应用 | |
| HK40062088A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| HK40062089A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| HK1230186A1 (en) | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | |
| HK1230186B (zh) | 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用 | |
| HK1127775A (en) | Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180126 |
|
| WD01 | Invention patent application deemed withdrawn after publication |